Daiichi Sankyo

Tenosynovial Giant Cell Tumor
FDA Grants Breakthrough Therapy Designation for Daiichi Sankyo and Plexxikon’s Investigational CSF-1R Inhibitor Pexidartinib (PLX3397)
02/11/2015 - 15:18
Daiichi Sankyo, Inc. and Plexxikon Inc., a member of the Daiichi Sankyo Group, today announced that the U.S. Food and Drug...
Helping to reduce preventable deaths
Daiichi Sankyo partners with World Thrombosis Day to promote awareness of venous thromboembolism and atrial fibrillation
09/10/2015 - 11:21
Daiichi Sankyo is proud to partner with World Thrombosis Day to promote vital global awareness of thrombosis, its causes, risk...
UK’s NICE recommends
Once-daily LIXIANA® (edoxaban) for preventing stroke and systemic embolism in patients with non-valvular atrial fibrillation
24/09/2015 - 11:49
The National Institute for Health and Care Excellence (NICE), the medicines cost-effectiveness body for England and Wales, has...
Daiichi Sankyo Initiates Hokusai-VTE Cancer Study
Evaluate the Role of Edoxaban in Patients with Venous Thromboembolism Associated with Cancer
19/06/2015 - 17:07
Daiichi Sankyo announces the initiation of Hokusai-VTE Cancer, a multinational study investigating edoxaban in venous...
Center for Connected Health and Daiichi Sankyo, Inc. Sign
Agreement to Co-Develop a Mobile App to Support Patients with Atrial Fibrillation
23/10/2014 - 16:47
The Center for Connected Health today announced a co-development agreement with Daiichi Sankyo, Inc. to create a mobile app to...
Announced
Daiichi Sankyo to Acquire Ambit Biosciences
29/09/2014 - 12:41
Daiichi Sankyo Company and Ambit Biosciences jointly announced today that they have entered into a definitive merger agreement...
Subgroup Analysis of ENGAGE AF-TIMI 48 Explores
Relationship Between Edoxaban Dose, Concentration, Anti- Factor Xa Activity and Outcomes
12/09/2014 - 15:48
Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced data from a subgroup analysis of the phase 3 ENGAGE AF...
No Japão
Daiichi Sankyo recebe aprovação para indicação adicional para o RANMARK®
26/05/2014 - 11:26
A Daiichi Sankyo anunciou que recebeu aprovação no Japão para uma indicação adicional do seu medicamento RANMARK® (denosumab,...
No Japão
Daiichi Sankyo pede autorização para produzir e comercializar a Methylene Blue®
18/03/2014 - 12:04
A Daiichi Sankyo anunciou esta segunda-feira, em comunicado de imprensa, que apresentou um pedido para a produção e...